Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETBX-011 + ALT-803 in CEA-expressing cancers
NCT03127098Phase 2Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Jun 2017
- Primary completion
- Dec 2017
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ETBX-011 and nogapendekin alfa inbakicept in thyroid cancer, colon cancer, ovarian cancer and 4 more, sponsored by ImmunityBio, Inc. Primary endpoint: Number of Participants With Dose-Limiting Toxicities at 9 weeks. Started Jun 2017; status: terminated.
02
Drugs
ETBX-011nogapendekin alfa inbakicept
03
Conditions
thyroid cancercolon cancerovarian cancerbreast cancerlung cancer
Beyond the preview
Go deeper on NCT03127098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03127098.